Core Insights - Pfizer has agreed to acquire Metsera for up to $7.3 billion, aiming to enter the lucrative weight-loss drug market [1][4] - Metsera shares surged 60% in premarket trading following the announcement, reflecting strong investor interest [1][4] - The acquisition price includes a cash offer of $47.50 per share, representing a 43% premium over the previous closing price [2] Group 1 - Pfizer will pay $47.50 per share for all outstanding shares of Metsera, with potential additional payments of up to $22.50 per share based on specific clinical and regulatory milestones [2] - Metsera's portfolio includes weight-loss medicine candidates designed to address unmet needs with fewer injections and improved efficacy [3] - Pfizer's CEO stated that the acquisition aligns with the company's strategy to focus investments on impactful opportunities, especially after halting development of another obesity treatment due to safety concerns [3] Group 2 - The transaction is expected to close in the fourth quarter, indicating a swift progression towards finalization [4] - Since beginning trading at the end of January, Metsera shares have increased by 25%, showcasing strong market performance prior to the acquisition announcement [4] - The acquisition reflects Pfizer's strategy to capitalize on the growing demand for weight-loss medications [4]